ProfileGDS5678 / 1416660_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 92% 90% 92% 90% 91% 93% 92% 93% 93% 92% 92% 91% 94% 92% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 17.5051292
GSM967853U87-EV human glioblastoma xenograft - Control 27.3328390
GSM967854U87-EV human glioblastoma xenograft - Control 37.6703692
GSM967855U87-EV human glioblastoma xenograft - Control 47.4451290
GSM967856U87-EV human glioblastoma xenograft - Control 57.5530691
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 17.5637893
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 27.5225192
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 37.7525693
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 47.8125193
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 17.5621692
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 27.6319292
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 37.4723391
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 48.040594
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 57.5869492